A pair of new studies describe infection- and vaccine-conferred immunity against the SARS-CoV-2 Omicron variant, with one showing that vaccinated people have good protection against BA.5 subvariant reinfection for at least 8 months after infection, and the other finding that the vaccine is 46% and 70% effective against infection and hospitalization, respectively, in children.
Recent Comments